NCT07532902 A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer Status RECRUITING Phase PHASE1
NCT07510334 VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07504796 ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Status RECRUITING Phase PHASE4
NCT07444619 A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas Status NOT_YET_RECRUITING Phase PHASE1
NCT07430202 A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) Status NOT_YET_RECRUITING Phase PHASE1
NCT07422779 Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia Status RECRUITING Phase NA
NCT07401875 A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) Status RECRUITING Phase PHASE1
NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Status NOT_YET_RECRUITING Phase PHASE3
NCT07355205 First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07293351 A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) Status RECRUITING Phase PHASE1/PHASE2
NCT07291076 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) Status RECRUITING Phase PHASE1/PHASE2
NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT07227012 Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. Status RECRUITING Phase PHASE1/PHASE2
NCT07188896 A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Status RECRUITING Phase PHASE2
NCT07166406 Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Status RECRUITING Phase PHASE3
NCT07155317 Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial Status RECRUITING Phase PHASE2
NCT07147101 Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment Status RECRUITING Phase N/A
NCT07128680 Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Status RECRUITING Phase PHASE1
NCT07000149 A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06968988 Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Status RECRUITING Phase PHASE1